Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months. This survival data along with radiographic improvements are indicative of positive treatment effects, which highlights the potential of IN8bio s genetically modified, chemotherapy-resistant gamma-delta T cells as a potential first-in-class therapy for patients with newly diagnosed glioblastoma.
Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham demonstrated that 92% of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months.
UAB is already a national leader in clinical trials. Here is how it plans to extend the benefits to even more Alabamians. uab.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from uab.edu Daily Mail and Mail on Sunday newspapers.
Kallie McDonald says following her heart and passion put her in a position to help women suffering from the same illness as her mom. Written by: Katherine Kirk Media contact: Brianna Hoge Kallie McDonald says following h.
Screenings will take a few minutes to conduct and will include a check for lesions and lumps on the neck or in the mouth. Screenings will take a few minutes to conduct and will include a check for lesions and lumps on th.